S&P 500   2,995.99 (-0.36%)
DOW   26,788.10 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
AMZN   1,765.73 (-1.12%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
S&P 500   2,995.99 (-0.36%)
DOW   26,788.10 (-0.15%)
QQQ   191.85 (-0.80%)
AAPL   239.96 (-0.23%)
FB   182.34 (-3.91%)
MSFT   136.37 (-1.49%)
AMZN   1,765.73 (-1.12%)
NVDA   195.61 (-0.20%)
MU   44.66 (-1.24%)
BABA   169.89 (-2.09%)
GE   9.06 (+3.07%)
TSLA   255.58 (+0.82%)
AMD   31.51 (-1.62%)
T   38.17 (-0.16%)
F   9.07 (+0.44%)
ACB   3.58 (-2.98%)
PRI   125.80 (+0.09%)
NFLX   266.69 (-4.09%)
BAC   31.20 (+0.58%)
GILD   65.86 (+1.00%)
DIS   132.40 (+1.64%)
Log in

SAGE Therapeutics Price Target & Analyst Ratings (NASDAQ:SAGE)

$139.69
-1.22 (-0.87 %)
(As of 10/22/2019 04:00 PM ET)
Today's Range
$138.60
Now: $139.69
$146.64
50-Day Range
$135.26
MA: $150.20
$171.67
52-Week Range
$79.88
Now: $139.69
$193.56
Volume447,266 shs
Average Volume478,377 shs
Market Capitalization$7.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.54

Analyst Ratings

SAGE Therapeutics (NASDAQ:SAGE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
14 Wall Street analysts have issued ratings and price targets for SAGE Therapeutics in the last 12 months. Their average twelve-month price target is $200.27, suggesting that the stock has a possible upside of 43.37%. The high price target for SAGE is $261.00 and the low price target for SAGE is $80.00. There are currently 1 sell rating, 1 hold rating and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.792.792.812.85
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $200.27$200.27$202.15$200.92
Price Target Upside: 43.37% upside19.02% upside21.42% upside22.17% upside

SAGE Therapeutics (NASDAQ:SAGE) Consensus Price Target History

SAGE Therapeutics (NASDAQ:SAGE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/7/2019OppenheimerLower Price TargetOutperform$200.00 ➝ $190.00Medium
7/24/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
7/24/2019William BlairReiterated RatingBuyLow
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$207.00Low
5/2/2019LADENBURG THALM/SH SHSet Price TargetBuy$220.00Low
4/26/2019Raymond JamesReiterated RatingMarket PerformMedium
4/25/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$195.00Low
4/8/2019Canaccord GenuitySet Price TargetBuy$220.00Low
2/22/2019GuggenheimInitiated CoverageBuy$205.00High
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$230.00 ➝ $213.00High
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformMedium
11/12/2018Leerink SwannInitiated CoverageUnderperform$80.00High
11/5/2018Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$259.00 ➝ $261.00Medium
11/1/2018CowenReiterated RatingBuy$207.00High
8/7/2018Stifel NicolausBoost Price TargetBuy$198.00 ➝ $239.00Medium
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$206.00Medium
2/28/2018SunTrust BanksBoost Price TargetBuy$203.00Low
2/23/2018Needham & Company LLCReiterated RatingBuy$193.00Low
12/7/2017BMO Capital MarketsReiterated RatingOutperform$203.00High
11/16/2017Bank of AmericaLower Price TargetBuy$103.00 ➝ $101.00N/A
11/10/2017Chardan CapitalUpgradeNeutral ➝ Buy$60.00 ➝ $140.00N/A
(Data available from 10/22/2017 forward)
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Featured Article: What is insider trading?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel